证券代码：300122 证券简称：智飞生物 公告编号：2025-46 重庆智飞生物制品股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会于 2025 年 8 月 6 日以电子邮件的方式向董事发出通知。 2、本次会议于 2025 年 8 月 15 日 10:00 在公司会议室以现场结合通讯方式 召开。 3、本次会议应出席并参加表决的董事 9 人，实际出席并参加表决的董事 9 人。 4、本次会议由公司董事长蒋仁生先生主持，公司监事、高级管理人员列席 了本次会议。 5、本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件及公司章程的规定。 二、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： 1、审议通过了《<2025 年半年度报告>及<2025 年半年度报告摘要>》 公司《2025 年半年度报告》及《2025 年半年度报告摘要》的编制程序符合 法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司 的实际经营情况。 具体内容详见 ...

重庆智飞生物制品股份有限公司 2025 年半年度报告全文 重庆智飞生物制品股份有限公司 2025 年半年度报告 2025 年 8 月 1 重庆智飞生物制品股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人蒋仁生先生、主管会计工作负责人李振敬先生及会计机构负 责人(会计主管人员)蒋彩莲女士声明：保证本半年度报告中财务报告的真 实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 报告期内，受民众接种意愿下降、市场需求变化等多重因素影响，公司 业绩显著承压，主要产品的市场推广销售工作未达预期。此情况与疫苗行业 上市公司整体业绩下行趋势一致。公司积极应对挑战，多措并举逐步化解风 险，有效保障了经营稳定，实现了平稳发展。 尽管行业短期承压，但在政策支持与技术创新的驱动下，中国疫苗市场 仍蕴藏巨大发展潜力与商业机遇。公司坚定不移走自主创新道路，布局丰富 多元的自主产品在研管线，加大科研创新投入与资源整合力度，以实现创新 技 ...

Group 1 - The stock price of Zhifei Biological Products Co., Ltd. (300122.SZ) decreased by 4.05%, closing at 22.76 yuan [1] - Zhifei's stock reached an all-time high of 231.19 yuan on May 17, 2021 [1] - Research analyst He Wei from Dongfang Caifu Securities maintained an "overweight" rating for Zhifei Biological in a report dated April 29, 2021, highlighting the dual drivers of self-research and agency [1]

Group 1 - The core viewpoint of the news is that Chongqing Zhifei Biological Products Co., Ltd. has experienced a significant decline in revenue and profit in the latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 13, 2025, the company's stock price closed at 23.72 yuan, with a 1.89% increase and a trading volume of 553,700 hands, amounting to 1.308 billion yuan in transaction value [1] - The net inflow of main funds today was 66.56 million yuan, accounting for 5.09% of the transaction amount, with large orders contributing significantly to this inflow [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 2.374 billion yuan, a year-on-year decrease of 79.16%, and a net profit attributable to shareholders of 305.14 million yuan, down 120.93% year-on-year [1] - The company has a current ratio of 2.298, a quick ratio of 1.029, and a debt-to-asset ratio of 36.85%, indicating its liquidity and financial stability [1] - Chongqing Zhifei Biological has made investments in 9 companies, participated in 1,170 bidding projects, and holds 34 trademarks and 81 patents, along with 63 administrative licenses [2]

转自：重庆日报 近日，重庆智飞生物制品股份有限公司全资子公司安徽智飞龙科马自主研发生产的四价流感病毒裂解疫苗（简称：四价流感疫苗）在安徽省合 肥市完成了全国首针接种，标志着智飞生物在流感疫苗领域实现重大突破。该疫苗不仅丰富了国内流感疫苗市场供给，也进一步夯实了智飞生 物在传染病防控领域的综合实力。 此次上市的四价流感疫苗采用世界卫生组织推荐的流感病毒株，适用于3岁及以上人群，该疫苗经培养、纯化、灭活、裂解工艺制备，具备良 好的安全性。 此外，智飞生物以国家公共卫生需求为导向，在流感疫苗领域布局了多款自主研发产品：四价流感病毒裂解疫苗（儿童型）和流感病毒裂解疫 苗（三价）已处于上市许可申请审评阶段；四价流感病毒裂解疫苗（ZFA02佐剂）已进入Ⅰ、Ⅱ期临床试验；三价流感病毒裂解疫苗（ZFA02 佐剂）已经获批临床。 自主研发驱动增长，多领域创新成果迎来爆发 流感疫苗的研发与上市仅是智飞生物自主研发创新的一个缩影。作为国内疫苗管线布局最丰富的公司之一，智飞生物始终坚持以自主创新为引 擎，关注全球传染病流行趋势，不断提升研发创新实力。公司多项疫苗新品种稳步推进：冻干人用狂犬病疫苗（人二倍体细胞）、15价肺炎球 菌结合 ...

Group 1 - The National Vaccine and Biotechnology Index (980015) rose by 1.92% as of August 13, 2025, with significant gains from constituent stocks such as Zhaoyan New Drug (603127) up 9.16%, Changshan Pharmaceutical (300255) up 7.86%, and WuXi AppTec (603259) up 7.24% [1] - Zhifei Biological's subsidiary achieved a major breakthrough by completing the first nationwide vaccination of its quadrivalent influenza vaccine in Hefei, Anhui Province [1] - Haitong International Securities noted that while overseas revenue for Chinese vaccine companies remains relatively low, more companies are actively expanding into international markets, with a steady increase in the number of vaccine product pre-certifications [1] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of July 31, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and Zhifei Biological (300122), collectively accounting for 64.94% of the index [2] - The Vaccine ETF Penghua (159657) closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [1]

Core Viewpoint - Zhifei Biological has achieved a significant breakthrough in the influenza vaccine sector with the successful administration of the first dose of its quadrivalent influenza virus split vaccine in Hefei, Anhui Province, marking a milestone in its independent research and development efforts [1][3]. Group 1: Product Development and Market Position - The quadrivalent influenza vaccine is based on virus strains recommended by the World Health Organization and is suitable for individuals aged 3 and above, demonstrating good safety through its production process [3]. - The company has multiple self-developed products in the influenza vaccine field, including a quadrivalent split vaccine for children and a trivalent split vaccine, which are currently under review for market approval [4]. - Zhifei Biological has established three major research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center, enhancing its capabilities in vaccine development and production [3]. Group 2: Research and Development Investment - In 2024, the company plans to invest 1.391 billion yuan in research and development, increasing its R&D personnel to 1,072, with a total R&D investment of nearly 6 billion yuan over the past three years [3]. - The company is focused on addressing national public health needs and has several vaccine products in various stages of development, including clinical trials and market approval processes [4]. Group 3: Global Expansion and Clinical Trials - Zhifei Biological's self-developed products have been exported to dozens of countries, with clinical or registration work ongoing in nearly 20 countries [4]. - The company is advancing multiple new vaccine varieties, including a freeze-dried human rabies vaccine and a 15-valent pneumococcal conjugate vaccine, which are in the market review stage [4].

Core Viewpoint - Zhifei Biological's 26-valent pneumococcal conjugate vaccine (PCV26) has initiated Phase I clinical trials in Australia, marking a significant step in enhancing the global influence of Chinese vaccines [1] Group 1: Vaccine Development - The PCV26 is the only high-valent vaccine developed independently in China that has entered clinical trials [1] - The vaccine is progressing smoothly in domestic clinical trials, indicating strong development capabilities [1] Group 2: Market Positioning - The PCV26 is expected to synergize with Zhifei's existing 23-valent pneumococcal polysaccharide vaccine and the 15-valent pneumococcal conjugate vaccine, covering the entire age spectrum from infants to the elderly [1] - This strategic positioning aims to enhance Zhifei's status in the global pneumococcal vaccine market [1] Group 3: International Expansion - The initiation of overseas clinical trials signifies a multi-dimensional upgrade in Zhifei's pneumonia product matrix, establishing a more complete and competitive product system [1] - This move is a solid step towards internationalization, laying a stable foundation for market expansion and deepening in the global arena [1]

Core Viewpoint - The launch of the quadrivalent influenza vaccine by Zhifei Biological's subsidiary marks a significant breakthrough in the influenza vaccine sector, enhancing the company's capabilities in infectious disease prevention [1][3]. Group 1: Vaccine Launch and Market Impact - The quadrivalent influenza vaccine has been developed to address the seasonal flu, which causes 3 to 5 million severe cases and 290,000 to 650,000 respiratory disease-related deaths globally each year [3]. - The vaccine is designed for individuals aged 3 and above and is produced using WHO-recommended influenza virus strains, ensuring good safety profiles [5][7]. - The introduction of this vaccine increases the availability of preventive options for the public, particularly benefiting high-risk groups such as infants, the elderly, pregnant women, and chronic disease patients [3][5]. Group 2: Research and Development Pipeline - The company has multiple influenza vaccine products in the pipeline, including a quadrivalent influenza vaccine for children and a trivalent influenza vaccine, both of which are in the application review stage for market approval [7]. - Other products under development include a quadrivalent influenza vaccine with adjuvant, currently in Phase I and II clinical trials, and a trivalent influenza vaccine with adjuvant that has received clinical approval [7][10]. - The company is also advancing various other vaccine candidates, including a freeze-dried rabies vaccine, a 15-valent pneumococcal conjugate vaccine, and a quadrivalent recombinant norovirus vaccine, among others [10][12]. Group 3: Strategic Vision and Future Plans - Zhifei Biological aims to enhance its independent innovation capabilities across various fields, including vaccines and bioproducts, while establishing a comprehensive "prevention & treatment" industry layout [12]. - The company is committed to addressing public health needs and aligning its product strategy with market demands and industry trends to contribute to global epidemic prevention efforts [12].

Core Viewpoint - The enthusiasm for share buybacks among listed companies has surged in 2023, with a significant increase in the number of buyback plans and the total amount allocated for these buybacks, reflecting a proactive approach to capital management and market confidence [1][2][3]. Group 1: Share Buyback Trends - As of March 16, 2023, 821 A-share companies have announced 830 buyback plans, with a total buyback limit exceeding 90 billion yuan [1]. - The number of companies engaging in "cancellation-type" buybacks has increased, with 57 new plans announced, indicating a focus on maintaining and enhancing stock prices [1][2]. - The total disclosed amount for buyback cancellations has reached 22.7 billion yuan, surpassing the total for the entire year of 2023 [2]. Group 2: Regulatory Support and Market Impact - The China Securities Regulatory Commission (CSRC) has expressed strong support for share buybacks, particularly cancellation-type buybacks, as a means to enhance shareholder returns and stabilize the market [2][3]. - New regulatory guidelines encourage companies to adopt buyback strategies, including the integration of buyback amounts into dividend payout calculations [2][3]. - The implementation of these guidelines is expected to lead to an increase in buyback frequency and amounts, thereby improving market confidence and stability [3]. Group 3: Leading Companies and Market Response - Major companies with market capitalizations exceeding 100 billion yuan, such as WuXi AppTec and Midea Group, are actively engaging in cancellation-type buybacks, setting a precedent for other firms [4][5]. - The announcement of substantial buyback plans has led to immediate positive stock price reactions, indicating investor approval and confidence in these strategies [5]. - The actions of leading companies are expected to have a demonstrative effect, encouraging other firms to adopt similar practices to enhance the overall investment environment [5].